Zinecard

Active Ingredient(s): Dexrazoxane
FDA Approved: * May 26, 1995
Pharm Company: * PHARMACIA AND UPJOHN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Zinecard Overview

Dexrazoxane hydrochloride (Zinecard by Pfizer in USA and Canada; Cardioxane by Novartis for EU and other countries) is a cardioprotective agent. It was discovered by Kurt Hellmann in 1972. Dexrazoxane is a sterile, pyrogen-free lyophilizate intended for intravenous administration. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.[1] Uses Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as ...

Read more Zinecard Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dexrazoxane

Recent Zinecard Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dexrazoxane
  • Injection: 250mg, 250mg/vial, 500mg, 500mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zinecard: (2 results)

Sorted by National Drug Code
  • 0013-8717 Zinecard 250 mg/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Pharmacia and Upjohn Company
  • 0013-8727 Zinecard 500 mg/50ml Intravenous Injection, Powder, Lyophilized, for Solution by Pharmacia and Upjohn Company

Other drugs which contain Dexrazoxane or a similar ingredient: (2 results)